||| Menü 
Firmenveranstaltungen, Neuemissionen

Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

Fusionen, Übernahmen

Personal, Belegschaft, Meldungen zu Produkten


Bankleitzahlen - online.de

Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease

Novartis International AG /
Novartis International AG: New patient survey highlights need for more action to
help severe asthma patients gain control of their disease
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

* Large-scale European patient survey found that 94% of severe allergic asthma
patients were unable to fully control their disease

* These new data underscore the disconnect between self-perceived control and
clinical reality; a potentially limiting factor in patients seeking support
to better control their condition

* Helping patients recognize the possibilities of living a life with properly
controlled asthma is central to a major new global patient engagement
program being launched by Novartis, called Billion Breaths

Basel, 17(th) June, 2017 - Novartis announced the results of a new survey of
904 severe asthma patients, presented today for the first time at the European
Academy of Allergy and Clinical Immunology (EAACI) Congress[1]. Data from the
'Still Fighting for Breath' survey demonstrate that, despite the widespread
availability of oral and inhaled treatments, asthma still places a huge burden
on the personal and professional lives of those living with the disease in

The new survey revealed that high levels of uncontrolled disease still exist
amongst adults and children with severe asthma. Asthma attacks (also known as
exacerbations) were reported to be extremely common. Nearly three quarters (74%)
of patients surveyed  experienced an attack serious enough to have required
treatment from a healthcare professional in the emergency room, ambulance or at
home.  Furthermore, almost a third (32%) of patients experienced three or more
exacerbations during this time period. While a majority of patients (54%)
experiencing an exacerbation physically recovered after treatment within 24
hours, these patients often remained psychologically affected for a prolonged
period of time after the exacerbation, with almost a fifth of them (19%)
reporting effects persisting over a week[1].

Importantly, this new research found a significant discrepancy between
"perceived" versus "real life" asthma control. Specifically, nearly half (46%)
of the patients surveyed had self-estimated themselves as being "controlled",
which is a marked contrast to the 6% of patients that were actually deemed as
"controlled" according to the Global Initiative for Asthma (GINA) clinical
guidelines. This discrepancy may be a limiting factor in patients seeking
support to control their condition.

"The results from this new survey are important as the data demonstrate that too
many patients in Europe are living with the daily burden of uncontrolled severe
asthma. As such, this patient population may be significantly under-served",
said Professor Antonella Muraro, one of the authors of the survey. "More needs
to be done and the first step is to bridge the gap between the perceptions of
'good' control vs reality, among people with asthma. We need to focus greater
efforts on empowering and educating those living with asthma to fight for better
outcomes and to help them achieve a life unrestricted by their condition."

In addition to revealing the high levels of uncontrolled disease, the survey
also underscored the disruptive impact that living with severe asthma has on the
lives of patients. Nearly nine out of ten patients reported that their condition
impacted their daily living (88%) and 84% reported that it impacted physical
activities, with almost all patients (97%) reporting it disturbed their sleep.
Significantly, half of the patients surveyed believe their professional lives
are negatively impacted by their condition.

In response to the survey findings Novartis is launching a new patient
engagement program, entitled Billion Breaths. The program will encourage people
to set activity goals and provide advice and support to help them achieve a life
less restricted by asthma [https://www.youtube.com/watch?v=kniyOgnpQr4].

About the asthma impact study in Europe
The study enrolled 904 adult patients (>=18 years) and children (6-17 years old)
suffering from severe persistent asthma.  It spanned several countries,
including the United Kingdom (n=190), Germany (n=170), France (n=170, Italy
(n=116), Spain (n=115) and Portugal (n=30).

Data were collected through an online survey between July 12 and October
31 2016. Data for adolescent and pediatric patients were obtained through
caregivers. Collection and analysis of all data was completed by GFK Health on
behalf of Novartis.

The severe asthmatic patients in this survey were diagnosed by respiratory
physicians (38%), general practitioners (33%), allergists (23%) and
pediatricians (5%). On average, adults were diagnosed with the disease 15 years
ago, adolescents seven years old and pediatrics three years ago. According to
the patients' understanding 49% considered themselves to have non-allergic
asthma (no additional tests were performed).

About asthma
Asthma is a global health problem[2] affecting an estimated 300 million people
worldwide[3]. It is a common long-term condition that can cause coughing,
wheezing, chest tightness and breathlessness.

There is no cure for asthma and treatment focuses on symptom relief[3]. Asthma
symptoms can either gradually or suddenly become worse. This is commonly
referred to as an "asthma attack" or "exacerbation". Severe exacerbations may
require hospital treatment and can be life- threatening[4]. However, when
appropriate treatment is instituted, asthma can be controlled without symptoms.

There are many different types of asthma. Severe asthma is a specific form of
asthma that requires specialist care and support.  It affects approximately 5%
of people with the condition. A patient with severe asthma may have breathing
difficulties and is also at risk of serious exacerbations[5].

Approximately 87% of severe asthma patients have taken oral corticosteroids
(OCS), for a reported average period of 20 days in the last six months[1]. The
updated 2017 GINA guidelines for asthma management state that patients should be
provided with written guidance on when/how to commence OCS treatment, typically
a short course (40mg/day for 5-7 days), and should also be advised of the
potential side effects that may occur when taking OCS[2].

This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as
"potentially," "launched," "may," "focus," "launching," "encourage," or similar
expressions. Such forward-looking statements reflect the current views of the
Group regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results expressed or implied by such statements. These
expectations could be affected by, among other things, risks and factors
referred to in the Risk Factors section of Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update it in the future.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
118,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit

Novartis is on Twitter. Sign up to follow @Novartis at
For Novartis multimedia content, please visit www.novartis.com/news/media-
For questions about the site or required registration, please contact

[1] Katsaounou P, Conde L G, Kroegel C et al. The challenges of living with
severe asthma in Europe. Abstract #858 presented at EACCI Congress 2017
[2] Global Strategy for Asthma Management and Prevention (2017).
prevention/ [Accessed March 2017]
[3] World Health Organization. Global surveillance, prevention and control of
chronic respiratory diseases: a comprehensive approach, 2007.
http://www.who.int/gard/publications/GARD%20Book%202007.pdf. [Accessed April
[4] NHS Choices - Asthma.
http://www.nhs.uk/conditions/Asthma/Pages/Introduction.aspx. [Accessed April
[5] Asthma UK, Severe asthma and difficult to control asthma.
[Accessed March 2017]

# # #

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Eric Althoff Claudia Paproth
Novartis Global Media Relations Novartis Pharma Communications
+41 61 324 7999 (direct) +41 61 696 5556 (direct)
+41 79 593 4202 (mobile) +41 79 560 4713 (mobile)
eric.althoff@novartis.com claudia.paproth@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF):

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via GlobeNewswire

 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Sehr gut

Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.092 Sekunden